... and for those new to the party, Zantrene is the world's First in Class and Best in Class FTO inhibitor. It has been previously approved in Europe and has numerous historic Phase 2 and 3 trials that prove efficacy and safety. These trials can be used for approval in the US because the program designed and under execution by current leadership has been carefully considered.
So far: - helps to overcome immunotherapy resistance - improves cancer elimination of doxorubicin (the most used chemotherapeutic drug in the world) - reduces heart damage from doxo - massive impact on extramedullary AML in the clinic - works on its own and in combo - and many, many more
RAC Price at posting:
$2.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)